GlassScriptPhysician profile
Joseph A Cook
NPI 1760639892
$2,562.90
in general payments reported to CMS, 2019-2025
28 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $76.67 · 2023: $232 · 2024: $363 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $493.96 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $324.27 | 2019-2025 | |
| Glaxosmithkline, LLC. | $289.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $180.16 | 2019-2024 | Airsupra |
| Amarin Pharma, INC. | $144.42 | 2019-2020 | |
| Abbvie INC. | $141.09 | 2023-2025 | Viberzi, Linzess, Creon |
| Lilly USA, LLC | $115.39 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $95.36 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $86.64 | 2023-2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $84.59 | 2023 | Rexulti, Nuedexta |
| Merck Sharp & Dohme LLC | $84.53 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.22 | 2024-2025 | Xifaxan, Trulance |
| Sanofi-Aventis U.S. LLC | $51.08 | 2019 | |
| Boston Scientific Corporation | $49.33 | 2025 | General - Therapies |
| Aimmune Therapeutics, INC. | $45.62 | 2024-2025 | Zenpep |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.80 | 2019-2025 | Spravato |
| Novartis Pharmaceuticals Corporation | $31.83 | 2019 | |
| Astellas Pharma US INC | $31.56 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $31.06 | 2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.16 | 2019-2020 | |
| Allergan, INC. | $26.05 | 2019-2020 | |
| Edwards Lifesciences Corporation | $23.55 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $21.23 | 2025 | Proclaim |
| Harmony Biosciences LLC | $20.81 | 2024 | |
| Neurocrine Biosciences, INC. | $20.71 | 2023 | Ingrezza |
| Medtronic, INC. | $16.19 | 2025 | Intellis Adaptivestim |
| Itamar Medical INC | $15.24 | 2023 | Watchpatone |
| Insulet Corporation | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.